Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587238 | 0.77 | MAPK14 (0.49) | MCHR1KCNH2MAPK14 | |
| SCHEMBL3602692 | 0.77 | MCHR1 (0.42) | MCHR1KCNH2MAPK14 | |
| SCHEMBL4601498 | 0.72 | MCHR1 (0.39) | MCHR1KCNH2MAPK14 | |
| SCHEMBL3587241 | 0.70 | MAPK14 (0.47) | MCHR1KCNH2MAPK14 | |
| SCHEMBL7641512 | 0.67 | MAPK14 (0.62) | MCHR1MAPK14 | |
| SCHEMBL1365787 | 0.64 | MCHR1 (0.71) | MCHR1KCNH2MAPK14 | |
| SCHEMBL4488171 | 0.64 | HTR6 (0.50) | MCHR1MAPK14 | |
| SCHEMBL4484736 | 0.62 | MAPK14 (0.76) | MCHR1KCNH2MAPK14 | |
| SCHEMBL4470408 | 0.62 | MAPK14 (0.64) | MCHR1KCNH2MAPK14 | |
| SCHEMBL1523159 | 0.62 | MAPK14 (0.67) | MCHR1KCNH2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |